Autolus Therapeutics (AUTL) Non-Current Deffered Revenue (2021 - 2025)
Autolus Therapeutics posted quarterly Non-Current Deffered Revenue of $253.4 million for Q1 2025, up 10.92% year-on-year from $228.5 million in Q1 2024, and up 3.61% on a QoQ basis from $244.6 million in Q4 2024.
Autolus Therapeutics (AUTL) has 5 years of Non-Current Deffered Revenue data on file, last reported at $253.4 million in Q1 2025.
- For the quarter ending Q1 2025, Non-Current Deffered Revenue rose 10.92% year-over-year to $253.4 million; the trailing twelve-month figure through Mar 2025 stood at $253.4 million (up 10.92% YoY), and the FY2024 full-year result was $244.6 million, up 43.13% from the prior year.
- Non-Current Deffered Revenue for Q1 2025 stood at $253.4 million, up from $244.6 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $253.4 million in Q1 2025 and bottomed at $47.0 million in Q4 2021.
- The 5-year median for Non-Current Deffered Revenue is $138.3 million (2023), against an average of $151.2 million.
- The widest annual swing landed in 2023, when Non-Current Deffered Revenue soared 168.44%; it then grew 10.92% in 2025.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $47.0 million in 2021, then soared by 167.78% to $125.9 million in 2022, then jumped by 35.74% to $170.9 million in 2023, then soared by 43.13% to $244.6 million in 2024, then advanced by 3.61% to $253.4 million in 2025.
- The last three Non-Current Deffered Revenue figures came in at $253.4 million (Q1 2025), $244.6 million (Q4 2024), and $248.9 million (Q3 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,384,976.65 Bn | 1,384,976.64 Bn | - | - |
| 2 | Alterity Therapeutics | 777,208.84 Bn | 777,208.81 Bn | - | - |
| 3 | Legend Biotech | 2,801.00 Bn | 2,800.10 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,226.01 Bn | 2,225.95 Bn | - | - |
| 5 | Akari Therapeutics | 605.66 Bn | 605.66 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 110.17 Bn | 102.92 Bn | 2.59 Bn | - |
| 7 | Regeneron Pharmaceuticals | 66.86 Bn | 58.11 Bn | 3.31 Bn | 225.10 Mn |
| 8 | Evaxion A | 65.12 Bn | 65.10 Bn | - | - |
| 9 | Alnylam Pharmaceuticals | 39.94 Bn | 36.94 Bn | 959.66 Mn | - |
| 10 | Autolus Therapeutics | - | - | -1.04 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 253.44 Mn |
| Dec 31, 2024 | 244.60 Mn |
| Sep 30, 2024 | 248.94 Mn |
| Jun 30, 2024 | 238.66 Mn |
| Mar 31, 2024 | 228.49 Mn |
| Dec 31, 2023 | 170.90 Mn |
| Sep 30, 2023 | 140.78 Mn |
| Jun 30, 2023 | 135.76 Mn |
| Mar 31, 2023 | 130.81 Mn |
| Dec 31, 2022 | 125.90 Mn |
| Sep 30, 2022 | 52.44 Mn |
| Jun 30, 2022 | 50.62 Mn |
| Mar 31, 2022 | 48.81 Mn |
| Dec 31, 2021 | 47.02 Mn |